research Tamoxifen for flutamide/finasteride-induced gynecomastia
Tamoxifen effectively treats gynecomastia without causing impotence.
Search
for
Sort by
Research
30-60 / 1000+ results research The selective androgen receptor modulator GTx‐024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double‐blind, placebo‐controlled phase II trial
Enobosarm significantly increased muscle mass and improved physical function in elderly men and postmenopausal women without serious side effects.
research Non-Steroidal Modulation of the 5-Alpha Reductase Axis: A Dual Therapeutic Strategy for Prostatic Chemoprevention and Androgenetic Alopecia
LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.
research Enzalutamide/finasteride/goserelin/zoledronic-acid
research Antiaging effects of equol: A unique antiandrogenic isoflavone metabolite and its influence in stimulating collagen deposition in human dermal monolayer fibroblasts
Equol may help with antiaging and skin health by boosting collagen and blocking certain hormones.
research Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069.
LGD1069 effectively prevents breast tumors in mice without toxicity.
research Effect of testosterone and its antagonists on knee range of motion through RXFP1 and RXFP2 regulation in rat model (911.12)
Testosterone reduces knee movement, while flutamide and finasteride increase it.
research Non-Steroidal Modulation of the 5-Alpha Reductase Axis: A Dual Therapeutic Strategy for Prostatic Chemoprevention and Androgenetic Alopecia
LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.
research Non-hemorrhage-related adverse effects of rivaroxaban
Rivaroxaban can cause liver injury, allergic reactions, blood vessel inflammation, and hair loss, but these side effects are rare.
research Rivaroxaban-induced hair loss
Rivaroxaban may cause hair loss.
research Alopecia With Endocrine Therapies in Patients With Cancer
Endocrine therapies for cancer significantly increase the risk of hair loss.
research Incidence of alopecia from endocrine therapies in cancer
Hair loss is a common, often overlooked side effect of hormone treatments for breast and prostate cancer.
research Insulin resistance and hair disorders, idiopathic hirsutism, and androgenic alopecia
There is no significant link between insulin resistance and certain hair disorders like idiopathic hirsutism and androgenic alopecia.
research Minimal systemic exposure of a new topical triazole antifungal, efinaconazole 10% solution, in patients with severe onychomycosis following 28-day treatment
Hair loss is a common but often unreported side effect of cancer treatments, especially for breast and prostate cancers.
research Onychomatricoma with classic features: Case report and review of the literature
Hair loss is a common side effect of hormone treatments for cancer.
research Analysis of breast health outcomes in women on oral 5-alpha reductase inhibitors: A single-center retrospective cohort study
Oral 5-alpha reductase inhibitors do not increase breast cancer or benign breast disorder risk in women.
research Sex hormones and related compounds, including hormonal contraceptives
Exposure to certain sex hormones can increase health risks, while some hormone therapies may offer benefits for specific conditions.
research 202 Activation of breast cancer cell proliferation by ROR-alpha through aromatase promoter
ROR-alpha may increase the growth of certain breast cancer cells by boosting aromatase, which could affect breast cancer prognosis.
research 5alpha-reductase inhibitors/finasteride.
research Alopecia in a premenopausal breast cancer woman treated with letrozole and triptorelin
Hair loss can occur as a side effect of certain breast cancer treatments, but minoxidil can help regrow hair.
research Identification of Anabolic Selective Androgen Receptor Modulators with Reduced Activities in Reproductive Tissues and Sebaceous Glands
Two new compounds were found to build bone and muscle without affecting reproductive organs and skin oil glands.
research Reduced estradiol synthesis by letrozole, an aromatase inhibitor, is protective against development of pentylenetetrazole-induced kindling in mice
Letrozole may help prevent seizures by reducing certain hormone levels.
research Effect of Red Clover Isoflavones over Skin, Appendages, and Mucosal Status in Postmenopausal Women
Red clover extract improved hair, skin, mood, sleep, and tiredness in postmenopausal women.
research Identification of xenobiotics interfering with 5 α -reductase (SRD5A2) activity
MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.
research News & Notes
Loop diuretics may double bone loss in elderly men, finasteride lowers prostate cancer risk but may increase high-grade tumors, abarelix reduces testosterone quickly, and transdermal testosterone offers minimal sexual benefit for women.
research Alopecia associated with strontium ranelate use in a 62-year-old woman
A woman experienced hair loss after taking strontium ranelate for osteoporosis.
research Design, synthesis and structure-activity relationships studies on steroidal aromatase and 5α-reductase inhibitors as anti-tumors
Modified steroidal inhibitors showed promise in treating hormone-dependent cancers.
research Androgens and Cardiovascular Disease
Male hormones may play a role in the development of heart disease, and more research is needed to understand their effects.
research The polycystic ovary syndrome: a position statement from the European Society of Endocrinology
The European Society of Endocrinology advises individualized long-term management for PCOS, focusing on lifestyle changes, accurate diagnosis, and treatments for associated health risks and symptoms.
research Pharmacology of anabolic steroids
Anabolic steroids can build muscle and strength but have risks and need more research on their clinical benefits and side effects.